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A central mechanism driving vascular disease in diabetes is immune cell-mediated inflam-
mation. In diabetes, enhanced oxidation and glycation of macromolecules, such as lipopro-
teins, insults the endothelium, and activates both innate and adaptive arms of the immune
system by generating new antigens for presentation to adaptive immune cells. Chronic
inflammation of the endothelium in diabetes leads to continuous infiltration and accu-
mulation of leukocytes at sites of endothelial cell injury. We will describe the central
role of the macrophage as a source of signaling molecules and damaging by-products
which activate infiltrating lymphocytes in the tissue and contribute to the pro-oxidant
and pro-inflammatory microenvironment. An important aspect to be considered is the
diabetes-associated defects in the immune system, such as fewer or dysfunctional athero-
protective leukocyte subsets in the diabetic lesion compared to non-diabetic lesions. This
review will discuss the key pro-inflammatory signaling pathways responsible for leukocyte
recruitment and activation in the injured vessel, with particular focus on pro- and anti-
inflammatory pathways aberrantly activated or repressed in diabetes. We aim to describe
the interaction between advanced glycation end products and their principle receptor
RAGE, angiotensin II, and the Ang II type 1 receptor, in addition to reactive oxygen species
(ROS) production by NADPH-oxidase enzymes that are relevant to vascular and immune
cell function in the context of diabetic vasculopathy. Furthermore, we will touch on recent
advances in epigenetic medicine that have revealed high glucose-mediated changes in the
transcription of genes with known pro-inflammatory downstream targets. Finally, novel
anti-atherosclerosis strategies that target the vascular immune interface will be explored;
such as vaccination against modified low-density lipoprotein and pharmacological inhibition
of ROS-producing enzymes.
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INTRODUCTION
A unifying feature of diabetic complications is chronic inflamma-
tion of the vasculature. The main vascular diseases that burden dia-
betic patients include nephropathy, retinopathy, neuropathy, and
atherosclerosis. Each of these conditions has a significant immune
component. In experimental and human diabetic nephropathy,
infiltrating macrophages, and T cells elaborate a host of pro-
inflammatory, pro-fibrotic, and pro-angiogenic factors that con-
tribute to disease development and progression in the kidney (Lim
and Tesch, 2012). Leukocyte adherence is causally associated with
endothelial cell injury and cell death in the diabetic retina (Joussen
et al., 2001) while infiltration of post-capillary venules with poly-
morphonuclear leukocytes is an early feature of proximal diabetic
neuropathy (Kelkar et al., 2000). Similar to the microvasculature,
immune-mediated inflammation of the macrovasculature plays a
central role in the pathogenesis of diabetes-accelerated atheroscle-
rosis (Libby et al., 2002). In this review, we examine the role of
the immune response in the pathogenesis of atherosclerosis as a
prototype for diabetes-associated vasculopathies.
TRIGGERS OF INFLAMMATION ELEVATED IN DIABETES
COMPARED TO THE NON-DIABETIC DISEASE STATE
Atherosclerotic lesions represent an excessive inflammatory, fibro-
proliferative response against different noxious stimuli (Ross,
1993, 1997). The diabetic milieu comprises of a host of potentially
harmful, immunogenic products including modified forms of
low-density lipoprotein (LDL), advanced glycation end products
(AGEs), reactive oxygen species (ROS) as well as pro-inflammatory
chemokines and cytokines. Elevated levels of LDL in patients
with diabetes are subject to modification by both oxidation and
glycation (Cohen et al., 2004). Furthermore, accelerated genera-
tion and vascular deposition of AGEs in addition to AGE inter-
actions with RAGE in diabetes initiate oxidative reactions that
promote the formation of oxidized LDL (oxLDL) (Basta et al.,
2004). Oxidation of LDL within the sub-endothelial space (intima)
enhances the pro-inflammatory properties of the endothelium
(Mazière and Mazière, 2009) and activates both innate and adap-
tive arms of the immune system (Binder et al., 2002; Hansson et al.,
2002).
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RELATIONSHIP BETWEEN THE ENDOTHELIUM AND
LEUKOCYTES IN EARLY ATHEROGENESIS
Chronic injury to the endothelium results in endothelial dysfunc-
tion, which can be defined as increased permeability, reduced
nitric oxide (NO) dependent vasodilatation as well as enhanced
pro-thrombotic and pro-inflammatory properties (Hink et al.,
2001; Davignon and Ganz, 2004; Hartge et al., 2007). Endothe-
lial dysfunction is a well established precursor of atherosclero-
sis, particularly in the setting of diabetes (Schalkwijk and Ste-
houwer, 2005). The diabetes-associated factors that impair nor-
mal endothelial function include increased synthesis of vaso-
constrictors such as angiotensin II (Ang II) and endothelin-1,
uncoupling of endothelial nitric oxide synthase (eNOS; leading
to reduced bioavailability of NO), and increased expression and
activity of ROS-producing enzymes (such as NADPH oxidases,
Nox) which trigger the expression of adhesion and chemotac-
tic molecules that promote the recruitment of inflammatory cells
to the arterial wall (Figure 1) (Hink et al., 2001; Guzik et al.,
2002; Lüscher et al., 2003; Hartge et al., 2007). Aortic lesions of
diabetic ApoE knockout (KO) mice show increased gene expres-
sion of pro-inflammatory molecules MCP-1,VCAM-1, and NF-κB
subunit p65 associated with increased pro-atherogenic cellularity
[macrophages, T cells, and smooth muscle cells (SMCs)] com-
pared to non-diabetic controls (Soro-Paavonen et al., 2008). In
line with these in vivo findings, human endothelial cells exposed
to high glucose conditions show increased leukocyte binding asso-
ciated with increased expression of E-selectin, ICAM-1, VCAM-1,
and MCP-1 through activation of NF-κB (Kim et al., 1994; Morigi
et al., 1998; Piga et al., 2007). In addition, recent studies have
revealed a striking association between glucose-induced endothe-
lial expression of adhesion molecules VCAM-1 and P-selectin as
well as the chemokines MCP-1 and fractalkine with Nox-derived
ROS production (Manduteanu et al., 2010; Gray et al., 2013). These
data indicate that diabetes-associated hyperglycemia and oxidative
stress promote leukocyte-endothelial cell interactions required for
the recruitment of leukocytes to the inflamed vessel.
ROLE OF SMOOTH MUSCLE CELLS IN DIABETES-MEDIATED
VASCULAR INFLAMMATION
Vascular SMCs play a central role in the initiation and progres-
sion of atherosclerosis (Doran et al., 2008). The expression of
cellular adhesion molecules and pro-inflammatory cytokines by
FIGURE 1 | Immune mechanisms engaged in diabetes-accelerated
atherosclerosis. Diabetes-associated hyperglycemia, hyperlipidemia, and
oxidative stress render the endothelium dysfunctional, leading to the
retention and oxidation of LDL molecules in the intimal space. The increased
expression of adhesion molecules E-selectin, ICAM-1, VCAM-1 at the
endothelial membrane, and upregulation of chemotactic molecules such as
MCP-1 facilitate the continuous infiltration of immune cells to the inflamed
aorta. Resident and monocyte-derived macrophages engulf LDL to form foam
cells which release a host of pro-inflammatory cytokines, protease, and ROS.
Activated T cells recruited from the circulation to the lesion also secrete
cytokines which amplify pro-inflammatory cellular immune responses in the
diabetic plaque. The diabetes-mediated increase in vascular inflammation
drives the development and progression of atherosclerosis. AGEs, advanced
glycation end-products; AT1R, angiotensin II type 1 receptor; ICAM-1,
intercellular adhesion molecule-1; LDL, low-density lipoprotein; MCP-1,
monocyte chemotactic protein-1; RAGE, receptor for advanced glycation end
products; ROS, reactive oxygen species; VCAM-1, vascular cell adhesion
molecule-1.
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lesional SMCs promote the accumulation and activation of leuko-
cytes in the atherosclerotic lesion (Braun et al., 1999; Raines and
Ferri, 2005). Of note, the expression of VCAM-1, ICAM-1, and
fractalkine is confined to SMCs within atherosclerotic vessels (or
lesion-prone areas) but not in healthy vessels (O’Brien et al., 1993;
Endres et al., 1997; Barlic et al., 2007); providing further evi-
dence of the pro-atherogenic role of these molecules. In response
to diabetes-associated atherogenic stimuli, such as Ang II (Ruiz-
Ortega et al., 2003) and ROS (Su et al., 2001), SMCs elaborate an
array of extracellular matrix proteins which facilitate the retention
of inflammatory cells and stabilization of the plaque including the
formation of a fibrous cap. Diabetes stimulates and sustains the
inflammatory “synthetic” phenotype of vascular SMCs. Hyper-
glycemia enhances the migration and proliferation of resident
SMCs within the intimal lesion which contributes to the accel-
erated formation of advanced atherosclerosis in diabetes (Suzuki
et al., 2001). Furthermore, exposure of cultured SMCs to high
glucose or AGEs significantly increases the production of ROS by
Nox enzymes (Inoguchi et al., 2000; Wautier et al., 2001; Gray
et al., 2013). More specifically, recent evidence has identified a
central role for the Nox1 isoform in glucose (Gray et al., 2013) and
Ang II-induced vascular superoxide production (Lassègue et al.,
2001). Therefore, vascular SMCs represent key players in diabetes-
mediated pro-inflammatory and pro-oxidant responses that drive
atherosclerosis.
MACROPHAGES ARE A SOURCE OF PRO-OXIDANT,
PRO-INFLAMMATORY MOLECULES WHICH FUEL
PRO-ATHEROGENIC PROCESSES IN THE VESSEL WALL
The macrophage plays a critical role in the initiation and pro-
gression of the atherosclerotic lesion. Circulating monocytes are
recruited to inflamed regions of the endothelium where they
engulf trapped LDL to form foam cells, histologically visible as
the early fatty streak (Ross, 1997). Uptake of glycated LDL by
human monocyte-derived macrophages occurs to a greater extent
than for native LDL (Klein et al., 1995). Interestingly, glycoxidized
LDL increases scavenger receptor expression to a greater extent
than glycated LDL or oxLDL alone (Lam et al., 2004). There-
fore, hyperglycemia in combination with elevated ROS in diabetes
increases macrophage avidity for LDL, and thus foam cell for-
mation, which ultimately activates other macrophages, infiltrating
adaptive “effector” cells as well as resident vascular cells leading to
accelerated atherosclerosis.
The lipid-laden macrophage acts as a frustrated phagocyte,
leaking ROS (refer to Nox section), and metalloproteases (MMPs)
into the extracellular space which catalyze the degradation of the
extracellular matrix proteins and trigger apoptosis of SMCs that
support the plaque’s fibrotic cap, ultimately enhancing the risk
of plaque rupture (Shah et al., 1995). Macrophages function in
response to environmental cues (Waldo et al., 2008). Monocyte-
derived macrophages cultured in high glucose (25 mM) conditions
display increased expression and activity of MMP-9 without affect-
ing metalloproteinase inhibitor (TIMP-1) expression (Death et al.,
2003). In line with these findings, Devaraj et al. (2006) showed that
monocyte superoxide anion release, pro-inflammatory cytokines
interleukin (IL) 6, and IL1β were significantly elevated in type 1
diabetic subjects compared with in control subjects. These striking
effects of hyperglycemia on macrophage activity may provide some
insight into the significantly increased incidence of plaque rup-
ture, thrombosis, and ultimately myocardial infarction in diabetic
patients compared to their non-diabetic counterparts (Silva et al.,
1995).
INTERACTIONS BETWEEN LEUKOCYTES WITHIN THE
LESION ENGAGE INFLAMMATORY PATHWAYS THAT DRIVE
ATHEROSCLEROSIS
Monocyte-derived macrophages act as sentinels of pro-
inflammatory signals, able to be activated by diverse stimuli and
release a range of mediators that contribute to pro- as well as
anti-atherogenic processes (Moore and Tabas, 2011). A plethora
of cytokines are detected in atherosclerotic vessels, and the reader
is directed to excellent reviews by Tedgui and Mallat (2006) and
Ait-Oufella et al. (2011). Activated macrophages and foam cells
release a number of pro-inflammatory cytokines and chemokines
which facilitate the continual recruitment of monocytes and T
lymphocytes to the atherosclerotic lesion. Of note, the predom-
inance of IFNγ-producing T lymphocytes in the lesion is likely
to contribute significantly to local macrophage activation (de
Boer et al., 1999). Further gene expression analysis of advanced
human plaques has revealed a cytokine profile indicative of a pro-
inflammatory, Th1-type cellular immune response (Frostegård
et al., 1999). The increased expression of CD40 and MHC-II
molecules on plaque macrophages (and other plaque-associated
vascular cells) also suggests an enhanced capacity of these cells
to function as antigen-presenting cells to T lymphocytes (Hans-
son et al., 1991; Li et al., 1993; Mach et al., 1997). The potent
immunostimulatory and pro-atherogenic effects of IFNγ are well
established (Gupta et al., 1997), and so interactions between
macrophages and T lymphocytes that continuously upregulate
IFNγ production are expected to contribute to the progression
of the lesion.
THE CYTOKINE PROFILE OF ACTIVATED VASCULAR
CELLS/LEUKOCYTES IS ALTERED IN THE DIABETIC SETTING
Macrophages represent a heterogeneous population of distinct
subsets capable of differentially affecting Th1- or Th2-type
responses (Mills et al., 2000). Lesion macrophages adopt predom-
inantly a pro-inflammatory and pro-atherogenic role indicative of
the M1-subtype (Khallou-Laschet et al., 2010; Wilson, 2010; Shal-
houb et al., 2011). Furthermore, hyperglycemia interferes with the
ability of IL4 to polarize macrophages to the alternatively activated
M2 state, characterized by wound repair and anti-inflammatory
functions (Auffray et al., 2009; Parathath et al., 2011). A compre-
hensive review of macrophage differentiation and activation path-
ways in atherosclerosis can be found by Shalhoub et al. (2011). In
a similar manner, hyperglycemia is associated with increased acti-
vation of pro-inflammatory human T lymphocytes and decreased
suppressor function of T regulatory cell subsets (Marfella et al.,
2003; Lindley et al., 2005; Stentz and Kitabchi, 2005). There-
fore, not only does the diabetic micro-environment amplify the
magnitude and array of new, potentially immunogenic stimuli
but it also skews the leukocyte repertoire in favor of adopting a
pro-inflammatory functional phenotype. Moreover, high glucose
may interfere with the immunomodulatory capacity of T cell and
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macrophage subsets leading to an unabated prolongation of the
inflammatory process.
Patients with diabetes have an increased risk of infection attrib-
utable to defects in both innate and adaptive immunity (Geerlings
and Hoepelman, 1999). Consistent with these findings in humans,
streptozotocin (STZ)-induced diabetes in rodents predisposes to
delayed innate (Chin et al., 2012) and adaptive (Vallerskog et al.,
2010) responses irrespective of the challenge, leading to increased
susceptibility to infection. High glucose conditions have been
shown to decrease T and B lymphocyte proliferation, diminish cell
viability, and increase apoptosis via mechanisms likely to involve
increased oxidative stress (Rubinstein et al., 2008). This seems
counter-intuitive in a disease characterized by secondary compli-
cations driven by immune cell-mediated inflammation, however
the high glucose and high ROS diabetic milieu provides the ideal
setting for chronic activation of innate and adaptive cells to non-
microbial, modified macromolecules (described in section above).
Therefore, it is important to discuss diabetes-induced alterations
in the immune system in the context of any insults (infection)
or complications (e.g., atherosclerosis) that accentuate as well
as catalyze further derangement in both arms of the immune
response.
SIGNALING PATHWAYS IMPORTANT TO
HYPERGLYCEMIA-INDUCED VASCULAR PATHOPHYSIOLOGY
AGE/RAGE
Advanced glycation end products and their cell surface receptor,
RAGE, have been implicated in the amplification and progres-
sion of immune-inflammatory responses that underscore diabetic
complications (Schmidt et al., 2001; Basta et al., 2004; Jandeleit-
Dahm et al., 2008; Bierhaus and Nawroth, 2009). Atherosclerotic
lesions in diabetic ApoE KO mice display increased accumulation
of AGEs and enhanced expression of RAGE (Kislinger et al., 2001;
Wendt et al., 2002; Soro-Paavonen et al., 2008). Ligation of RAGE
by AGE stimulates endothelial pro-inflammatory gene expression
(VCAM-1, E-selectin) and ROS production in a NADPH-oxidase
dependent manner (Schmidt et al., 1995; Wautier et al., 2001; Higai
et al., 2006). In macrophages, AGE–RAGE interaction prompts
cell chemotaxis and cytokine release via a mechanism involving
the activation of NADPH oxidase (Kirstein et al., 1990; Wautier
et al., 2001). RAGE also appears to play a role in T lymphocyte
activation and differentiation, mediating Th1-type responses such
as the synthesis of IFNγ (Chen et al., 2008). Recent work by Aki-
rav et al. (2012) found that RAGE is expressed intracellularly in
human T cells following TCR activation but constitutively on T
cells from patients with diabetes. The current evidence supports a
critical role of AGE/RAGE signaling in the chronic activation of the
immune-inflammatory processes that accelerate atherosclerosis in
diabetes.
ANG II/AT1R
The renin-angiotensin system (RAS) plays an important role in the
regulation of vascular contractility and also represents a primary
target for diabetes-induced vascular dysfunction and inflamma-
tion. Most of the known pathophysiological effects of Ang II are
mediated via the activation of the Ang II type 1 (AT1) recep-
tor. The production of Ang II and the expression of its AT1R
are upregulated in the aorta of diabetic mice (Candido et al.,
2002, 2004). Signaling via the AT1R has been shown to upregulate
the RAGE pathway in diabetic atherosclerosis (Ihara et al., 2007).
Furthermore, Ang II induces activation with increased adhesion
molecule expression in endothelial cells, monocytes, and T lym-
phocytes (Hahn, 1994; Tummala et al., 1999; Hoch et al., 2009).
Most of the signaling events secondary to Ang II-AT1R binding
are redox sensitive, such as NFκB activation, and rely on the pro-
duction of ROS by Nox enzymes (Pueyo et al., 2000; Alvarez and
Sanz, 2001; Liu et al., 2003). Treatment of diabetic mice with an
AT1R blocker such as Candesartan attenuated ROS production
and Nox activity leading to improvements in endothelial function
(Oak and Cai, 2007). Recent work by Valente et al. (2012) revealed
a direct physical association between the AT1R and the Nox1-
NADPH-oxidase isoform in vascular SMCs, however the potential
functional and regulatory implications of this relationship remain
to be explored in the context of hyperglycemia. A common feature
of AGE and Ang II signaling is the convergence on Nox-derived
ROS as secondary mediator molecules required to elicit the effects
of RAGE and AT1 receptor binding, respectively.
NOX/ROS
Hyperglycemia induces activation of the Nox family NADPH-
oxidase enzymes and the consequent ROS production contributes
to the pathophysiological complications of diabetes (Gao and
Mann, 2009). Nox enzymes are the major source of ROS in the
vessel wall, differentially expressed in vascular and infiltrating
inflammatory cells (Griendling and Ushio-Fukai, 1997; Lassègue
and Clempus, 2003). In particular, the isoforms Nox1, Nox2, Nox4,
and Nox5 play important roles in a wide range of physiological and
pathological processes relevant to cardiovascular disease (Sorescu
et al., 2002; Bedard and Krause, 2007; Lassègue and Griendling,
2010). Increased ROS production in the diabetic aorta positively
correlates with upregulated expression and activity of Nox1, Nox2,
and Nox4 (Guzik et al., 2002; Wendt et al., 2005; Hwang et al.,
2007). Nox1 KO mice are protected from endothelial dysfunc-
tion in diabetes (Youn et al., 2012) while studies in Nox4 KO
mice have reported a vasculo-protective role for endogenous Nox4
(Schröder et al., 2012). Furthermore, recent work by Gray et al.
(2013) in Nox1 and Nox4/ApoE DKO mice identified a key role
for Nox1 but not Nox4-derived ROS in diabetes-accelerated ath-
erosclerosis which is consistent with previous reports suggesting
different (patho)physiological functions for Nox isoforms in the
vasculature.
Reactive oxygen species are both a product, and modulator,
of leukocyte recruitment, activation, and function. Ligation of
VCAM by leukocytes activates endothelial NADPH oxidase which
results in enhanced ROS production (Deem and Cook-Mills,
2004). In macrophages, Nox2 (gp91phox) is the major source of
ROS contributing to the respiratory burst, while Nox4 is inducible
by oxLDL (Lee et al., 2010; Tavakoli and Asmis, 2012). T lympho-
cytes also express a phagocyte-type Nox that is activated after TCR
stimulation (Jackson et al., 2004). Further activation of vascular
Nox by NFκB-dependent pro-inflammatory cytokines, including
TNFα, reaffirms the relationship between oxidative stress and
immune-mediated inflammation in diabetes (Park et al., 2006;
Gauss et al., 2007; Miller et al., 2007). The potential impact of
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diabetes-mediated changes in Nox on ROS-sensitive leukocyte
functions represents a relatively unexplored area of investigation.
ATHERO-PROTECTIVE MECHANISMS: FOCUS ON
ANTIOXIDANTS
We have discussed some of the key pro-inflammatory, pro-
atherosclerotic effects of Ang II/AT1R and AGE/RAGE signaling
pathways that are aberrantly activated in response to hyper-
glycemia. However, it is important to note that these same path-
ways can elicit anti-inflammatory effects, and the reader is encour-
aged to consult Goh and Cooper (2008), Daugherty et al. (2010),
and Thomas et al. (2010) for detail on alternative AGE recep-
tors, AT2R, and ACE2. While pro-inflammatory signaling cascades
tend to predominate in diabetes, the inactivation of some impor-
tant athero-protective pathways by the diabetic milieu further
exposes the diabetic vasculature to pro-oxidant insults that accel-
erate atherogenesis. Major anti-oxidant defense systems such as
superoxide dismutases (SODs), and glutathione peroxide 1 (Gpx1)
are critical in the maintenance of redox balance in the intracellu-
lar and extracellular spaces. Diabetic ApoE/GPx1 DKO mice show
significantly more aortic atherosclerosis associated with enhanced
macrophage recruitment, RAGE, and VCAM-1 expression com-
pared to the diabetic ApoE KO mice (Lewis et al., 2007). Therefore,
a decrease in anti-oxidant capacity in diabetes in combination with
elevated ROS production from various sources, contributes to the
pro-oxidant diabetic milieu (Feillet-Coudray et al., 1999; Vessby
et al., 2002).
AN EMERGING ROLE FOR EPIGENETIC MODIFICATIONS IN
DIABETIC COMPLICATIONS
The effect of hyperglycemia on the transcription and translation
of genes coding proteins involved in the inflammatory response
persist beyond the time of exposure. A growing number of stud-
ies utilizing the bio-informatic power of epigenetic medicine
have already identified chromatic modifications characterized by
histone methylation and acetylation sites, and their associated
enzymes, involved in glucose-mediated changes in gene expression
(Brasacchio et al., 2009; Pirola et al., 2011; Keating and El-Osta,
2012; Miao et al., 2012). El-Osta et al., identified a role for Set7,
a H3K4-specific methyltransferase, in transient hyperglycemia-
mediated chromatin changes at the promoter of the NF-κB subunit
p65 resulting in increased gene expression of p65, MCP-1, and
VCAM-1 in vascular endothelial cells that persist during subse-
quent normoglycemia; a phenomenon termed“glycemic memory”
(El-Osta et al., 2008; Okabe et al., 2012). Similarly, ex vivo culture of
vascular SMCs from type 2 diabetic db/db mice exhibit a sustained
atherogenic and pro-inflammatory phenotype with concomi-
tant depletion of the H3K9-specific methyltransferase, Suv39h1,
despite restoration of euglycaemia (Villeneuve et al., 2010). Fur-
ther investigations suggest that regulation of pro-inflammatory
gene expression by Suv39h1 is dependent on glucose-mediated
elevations in the microRNA (miR)-125b (Villeneuve et al., 2008).
Recent advances in cancer research have demonstrated cross-
talk between miR machinery and DNA methylation (Ting et al.,
2008; Yan et al., 2011). While there is growing evidence support-
ing glucose-induced alterations in chromatin structure and miR
expression in the pathogenesis of diabetic complications (Reddy
and Natarajan, 2011; Villeneuve et al., 2011), little is known about
the interplay of these components in diabetes.
Epigenetic mechanisms play a central role in the pathobiol-
ogy of endothelial (Piconi et al., 2004; El-Osta et al., 2008) and
SMCs (Villeneuve et al., 2008, 2010) in high glucose conditions,
yet remain a relatively unexplored area in the context of immune
cell-mediated vascular inflammation. Monocytes and lympho-
cytes, immune cells with well-characterized roles in atherosclerosis
(Hansson and Hermansson, 2011), display distinct profiles of
histone acetylation and methylation in diabetic patients with cor-
responding changes in inflammatory gene expression (Miao et al.,
2007, 2008). Additionally, Miao et al. (2012) identified marked dif-
ferences in human leukocyte antigen (HLA)-expression in mono-
cytes from diabetic patients compared to controls which related
to differences in the histone acetylation status of the HLA pro-
moter region. In light of these findings, it would be very interesting
to explore the epigenetic status of various immune cell popula-
tions, especially adaptive immune cells which naturally develop
“memory” subsets [present also in complex atherosclerotic lesions
(Stemme et al., 1992)] that respond rapidly to repeated chal-
lenges of the same antigen. Poorly controlled diabetes whereby
blood glucose regularly spikes to pathological levels may be suf-
ficient to reactivate memory subpopulations, leading to rapid
and robust inflammatory responses that accelerate atherosclero-
sis and increase risk of plaque rupture events in diabetes. Future
studies examining chromatin modifications in immune cells inti-
mately involved in the pathogenesis of diabetic complications
will improve our understanding of the mechanisms underlying
glycemic memory and the sustained pro-inflammatory state of
the diabetic vasculature.
THERAPEUTIC STRATEGIES WITH CLINICAL PROMISE
Therapeutic strategies against diabetes-associated atherosclerosis
can be targeted at various stages of disease pathogenesis. Interven-
tions that block signaling via RAGE (Soro-Paavonen et al., 2008)
or the AT1R (Candido et al., 2004) have proved effective in reduc-
ing plaque formation in mouse models with diabetes. There is a
growing body of evidence to suggest that a large number of the
pro-inflammatory signaling cascades triggered by hyperglycemia
converge on Nox-derived ROS making it an excellent target for
novel therapies (Sedeek et al., 2012). To date, studies examining
pharmacological inhibition of Nox-derived ROS in experimental
models of chronic inflammatory diseases including liver fibrosis
(Jiang et al., 2012), diabetic nephropathy (Sedeek et al., 2010), and
atherosclerosis (Gray et al., 2013) have yielded positive results,
and much anticipation surrounds the clinical evaluation of spe-
cific Nox inhibitors (Kim et al., 2011). The effects of immune
modulation on atherosclerosis and the emerging inflammatory
cell/cytokine-directed therapies have been addressed in a recent
review by Little et al. (2011). Increasing evidence demonstrates a
strong association between circulating oxLDL-immune complexes
and cardiovascular risk in diabetic patients (Lopes-Virella et al.,
1999, 2011a,b; Orchard et al., 1999). Immunization with oxLDL
or other candidate plaque antigens have shown promise in ani-
mal models (Palinski et al., 1995; Ameli et al., 1996; George et al.,
1998) however evidence demonstrating the pathogenic proper-
ties of antibodies to modified LDL (summarized by Lopes-Virella
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and Virella, 2010) may hamper the clinical utility of this strat-
egy. Cytokine-based therapies that skew macrophage or T cell to
anti-inflammatory and regulatory phenotypes have been effective
in mouse models of atherosclerosis (Namiki et al., 2004; Sasaki
et al., 2009; Cardilo-Reis et al., 2012). The establishment of highly
atherosclerosis-specific antigens or cytokines in combination with
cell- or tissue-focused delivery systems will be pre-requisites for
more fine-tuned immunomodulatory therapies. Overall, signifi-
cant challenges continue to plague attempts to translate laboratory
findings to the clinic and greater emphasis on human studies
is required to fully realize the therapeutic potential of targeting
immunological mechanisms in disease (Davis, 2008; Libby et al.,
2011). A systems approach to immunology, as outlined in a recent
review by Brodin et al. (2013), may impart more successful clinical
results for novel therapies.
CONCLUSION
An extensive body of experimental and clinical evidence has
improved our understanding of the immune-inflammatory
processes involved in vascular disease. However, there are still
considerable challenges in alleviating the burden of vascular com-
plications in diabetic patients. In this review we have discussed
that, in addition to high glucose, pathological increases in AGEs,
Ang II, and ROS induce a chronic state of vascular inflammation.
Specifically, we have described how diabetes-mediated aberrations
in vascular-leukocyte interactions result in increased accumula-
tion of pro-inflammatory leukocytes to the atherosclerotic vessel
wall. Future studies that explore the pro-inflammatory effects
of RAGE, AT1R, or Nox-signaling pathways in the diabetic vas-
culature are likely to offer novel ways of targeting the immune
responses inappropriately activated or inactivated in diabetes.
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